MUMBAI (Reuters) - Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.
The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.
Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.
(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)
Trending On Reuters
Earthquake Strikes Nepal
A powerful earthquake struck Nepal and sent tremors through northern India on Saturday, killing more than 1,000 people, toppling a 19th-century tower in the capital Kathmandu and touching off a deadly avalanche on Mount Everest. Full Article | Nepal earthquake epicentre map
RBI chief Rajan calls for formal financing routes for farmers - report Full Article
India to host Afghan leader, seeks to regain ground lost to China, Pakistan Full Article